COVID‐19 in hospitalized liver transplant recipients: An early systematic review and meta‐analysis

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly transmissible disease and entails significant mortality. The COVID-19 pandemic has already affected over 89 million people globally, with a fatality rate of 2%-6%. 1 The infection is of significant health concern in the elderly as well as populations with underlying comorbidities such as hypertension, diabetes mellitus, and chronic lung diseases. SARS-CoV-2 carries a higher risk of adverse outcomes in patients with specific disease states including chronic liver disease. SARS-CoV-2 virus can have higher adverse outcomes in patients with comorbidities, including chronic liver disease and liver

Consequences of the first and secondCOVID‐19 wave on kidney transplant recipients at a large Indian transplant centre

“… 20 The observed high‐case fatality in the elderly transplant recipients could be due to age‐associated comorbidities. 30 Our study had findings similar to this analysis of the Spanish Registry. 20 The interaction between age and time post‐kidney transplant should be considered when selecting recipients for transplantation in the COVID‐19 pandemic.…”

T cell–mediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19

“…All‐cause mortality rates among SOT recipients hospitalized due to COVID‐19 during the first pandemic wave have been reported to exceed that of the general population 1,3 . Although outcomes for LT recipients seem to be relatively better as compared to other transplant groups, the pooled estimate for in‐hospital mortality in a recent meta‐analysis reached 20% 14 . However, it has been recently proposed that the more severe course observed for post‐transplant COVID‐19 could be attributed to the higher burden of comorbidities and more common presence of risk factors for poor outcome (such as older age or acute kidney injury) rather than to the transplant status itself 15–18 .…”

Mucormycosis as SARS-CoV2 sequelae in kidney transplant recipients: a single-center experience from India

“…There is an extensive literature in the context of clinical profile and outcome of COVID-19 in SOT [14] including kidney [15][16][17], liver [18], lung [19], and heart [20,21]. Transplantation activity ceased around the world during the COVID-19 peak, but it is estimated that postponing transplantation will result in excess of deaths [22] and hence depending on the COVID-19 surge and available resources, the transplantation should be resumed.…”

“…Mild cases (73% vs 43%; p-value = 0.1) were higher and there were fewer cases (20% vs 9%; p-value = 0.69) with severe COVID-19 in post-COVID-19 mucormycosis. Among the laboratory profile, lymphopenia [12 (10-18) vs 20 (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26); p-value = 0.15] and higher neutrophil-lymphocyte ratio [7 (4.6-8.3) vs 3.85 (3.3 -5.8); p-value = 0.5] was more associated with post-COVID-19 mucormycosis.…”